Showing results (51-60 of 75) with videos related to
Sort By:
Pageof 8
Leukemia & Lymphoma|April 4, 2019
Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantationOfrat Beyar-Katz, Noa Lavi, Shimrit Ringelstein-Harlev, et al.European Journal of Haematology|May 31, 2023
Venetoclax-based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemiaJonathan Canaani, Avraham Frisch, Daniel A Pollyea, et al.Annals of Hematology|May 8, 2026
MRD conversion during oral azacitidine maintenance correlates with outcomes in predominantly favorable-risk AMLNoa Hurvitz, Irina Amitai, Ilana Levy, et al.Bone Marrow Transplantation|November 14, 2021
Feasibility and efficacy of salvage allogeneic stem cell transplantation in AML patients relapsing after autologous stem cell transplantationEvgenii Shumilov, Inna Shakhanova, Johanna Flach, et al.Journal of Medical Genetics|March 13, 2019
Homozygosity for CHEK2 p.Gly167Arg leads to a unique cancer syndrome with multiple complex chromosomal translocations in peripheral blood karyotypeTamar Paperna, Nitzan Sharon-Shwartzman, Alina Kurolap, et al.American Journal of Hematology|October 6, 2015
Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the "3 + 7" induction regimen for acute myeloid leukemiaYishai Ofran, Ronit Leiba, Chezi Ganzel, et al.American Journal of Infection Control|November 27, 2013
Eradication of carbapenem-resistant Enterobacteriaceae gastrointestinal colonization with nonabsorbable oral antibiotic treatment: A prospective controlled trialIlana Oren, Hannah Sprecher, Renato Finkelstein, et al.Blood Advances|November 27, 2019
BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a studyTsila Zuckerman, Ron Ram, Luiza Akria, et al.Leukemia & Lymphoma|May 19, 2020
Venetoclax is safe and efficacious in relapsed/refractory AMLChezi Ganzel, Ron Ram, Alexander Gural, et al.British Journal of Haematology|May 23, 2024
Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemiaEitan Kugler, Inbar Cohen, Irina Amitai, et al.Pageof 8